|
|
Post by peppy on Mar 8, 2018 8:16:31 GMT -5
Come on Sla, Sports, Peppy, seanismorris, digger, let’s see some thumbs up here. Afrezza will sell when it gets health insurance. I Have already seen love story. "Love means never having to say you are sorry." If we want Afrezza to sell, we want all endocrinologists/all general health physicians to become type one diabetics. It will not take long for them to make the switch. (DR. Edelman case in point.) When Sanofi dropped Afrezza, there are threads filled with my typing saying, "we need afrezza users walking around the ada with continuous glucose monitors." then I typed out, on the stage, two people with CGM eating a meal, at the AFREZZA both. These ideas have been typed out before. Hopefully with the STAT study, MNKD and Afrezza will be able to show the continuous glucose monitors. Nothing saids Afrezza better than giving the blind, site. The commercial MNKD has is fine. We need insurance. We need physicians with eye site. |
|
|
|
Post by lennymnkd on Mar 8, 2018 8:27:14 GMT -5
Al even provided that “sight” TICKER SYMBOL... eyes
|
|
|
|
Post by kc on Mar 8, 2018 11:02:04 GMT -5
|
|
|
|
Post by akemp3000 on Mar 8, 2018 11:36:13 GMT -5
Celebrities or pseudo celebrities are good but the only thing that really counts for an ad, be it print, online or TV, is whether or not the viewer absorbs the message. IMO, Hollywood, music and sporting celebrities can get quick attention but the general public now seems to be tuning out and even resisting their message. There are a few celebrity superstar exceptions but none of those are probably affordable. I like "Stop the Spike" as a message because it's the biggest issue facing diabetics at meal time and one to which they can all relate. Due to regulations, Mannkind can't claim that Afrezza stops the spike but they can bring attention to this being the goal. This would emphasize Afrezza's greatest strength plus the greatest weakness of competitors. This could also include the importance of a quick return to baseline or time-in-range. Hopefully the label change and STAT study are giving Dr. Kendall ammunition to help Mannkind's marketing team come up with a more powerful commercial that will be quickly understood and absorbed.
|
|
|
|
Post by lojothehus on Mar 8, 2018 11:49:58 GMT -5
There was nothing fine about MNKD's first commercial. It was dismal at best. Celebrities and sports figures are always excellent tools in advertising because they attract attention, meaning that people will listen to whatever it is that they are promoting for various reasons. MNKD should stress the following in their advertisements: No Needles, better A1C's, Rapid Acting, and Convenience.
|
|
|
|
Post by mytakeonit on Mar 8, 2018 13:51:03 GMT -5
kc - does Robin use Afrezza?
She is so busy I got tired just reading her bio ... Ha!
|
|
|
|
Post by kc on Mar 8, 2018 21:33:07 GMT -5
kc - does Robin use Afrezza? She is so busy I got tired just reading her bio ... Ha! Not that I know of, but MannKind should find a fitness person and get them engaged. Lots of young #T1D’s who need a good role model. she seems to be a hip type person. Would fit the demographic of the 20 to 40 year old wanting to take charge of their life and diabetes. The non-passive diabetic. |
|
|
|
Post by kc on Mar 10, 2018 13:00:44 GMT -5
Happened to see this article to day about Sanofi and their problem selling their wonder drug cholesterol-lowering drug Praluent. That is the same drug they had the lawsuit with Amgen on and lost. But if you read the article you will see that one of the issues that both Sanofi and Amgen have with the drug is the cost to the payer (insurer) Its way too high and they push back on letting patients receive it. So they have worked on a new Strategy to lower the price to the payer and create a more outcome based prescribing model.
"Now Regeneron and Sanofi are going one step further, agreeing to lower the price for Praluent to match an independent analysis that found it would be cost-effective for the highest-risk patients at a net cost of $4,500 to $8,000 a year. The companies added one condition to the lower price: that health insurers agree to remove the restrictions, like extensive tests and paperwork, that make prescribing the medicine an arduous process for doctors.
“We have to get the whole world to realize this is cost-effective for society and we have to get this drug to the patients who will benefit the most,” said George Yancopoulos, chief scientific officer at Tarrytown, New York-based Regeneron.
www.bloombergquint.com/business/2018/03/10/regeneron-sanofi-cut-heart-drug-s-price-as-trial-disappoints
This is probably the same direction that MannKind HAS to take to become a preferred Insulin product as the Healthcare industry is changing rapidly. I have to just wonder if Mike C knew this in hiring of Dr. David Kendall. MannKind has to work with payers to show Afrezza is the most cost effective Insulin product at either today's cost or a negotiated fixed price cost to the payer in order to gain critical mass. Remove restrictions and make it easier to prescribe Afrezza and we will give you more cost effective pricing. Perhaps a subscription based program.
Payers are adding the term OUTCOME BASED SOLUTIONS to their talking points and it evident as you see some of the recent marriages. CVS Buying Aetna Cigna Buy Express Scripts. Berkshire Hathaway/Amazon / JP Morgan Healthcare joint venture.
Payers want good outcomes for patients at a cheaper prices. |
|
|
|
Post by wgreystone on Mar 10, 2018 13:27:19 GMT -5
What I am worried about MNKD management team is if they really understand what is holding back doctors from prescribing Afrezza. Being on the market for three years yet Afrezza is not covered by many Medicare plans, is just unbelievable.
|
|
|
|
Post by akemp3000 on Mar 10, 2018 14:40:40 GMT -5
What I am worried about MNKD management team is if they really understand what is holding back doctors from prescribing Afrezza. Being on the market for three years yet Afrezza is not covered by many Medicare plans, is just unbelievable. Dr. Kendall was a fantastic recent hire that should significantly improve this issue moving forward as he speaks the diabetes language fluently. |
|
|
|
Post by rombic33 on Mar 10, 2018 15:03:37 GMT -5
That is a great hire indeed, but I do worry (a bit) that MNKD already had great hires in the previous years.
|
|
|
|
Post by peppy on Mar 10, 2018 15:26:08 GMT -5
What I am worried about MNKD management team is if they really understand what is holding back doctors from prescribing Afrezza. Being on the market for three years yet Afrezza is not covered by many Medicare plans, is just unbelievable. MNKD was not in great finical shape when Sanofi deal came through. Had the deal worked out like this.. Sanofi saw CGM coming and worked with insurance while trying to improve the label.... perhaps. I was so stupid, I thought doctors could order non inferior prescriptions and they would be covered. I did not realize to ask or read, that physicians have prescriptions that are covered by insurance, and if the label is equal, the insurance company gets to decide which one/ones the business cover. What MNKD/AFREZZA has going for it, is the continuing glucose monitor documentation of superior control, and our people say no hypoglycemia. so now provide it. At some level continuing glucose monitors proving it everyday. MNKD screwed up the dosing guidelines. when it came out it was being dosed 1:1 with subq. No follow up dose. The initializers figured it out. Sad story. Regardless... it is a toe to toe battle with insurance. I will say, insulin has always be difficult to dose. The diabetic had to be precise to avoid the bg low, because they were going to get the bg high. Diabetics had had to be a fearful of insulin. Afrezza is different. Insulin you can take. Is holding physicians back? What is your take wgreystone? |
|
|
|
Post by akemp3000 on Mar 10, 2018 16:15:17 GMT -5
IMO "communication" has been a real problem with Mannkind over the years. It raised its head first when they weren't prepared for Martin Shkreli's surprise communication with the FDA. It was a problem highlighted when the Sanofi deal soured. It's been a problem with titration. It's been a problem with marketing. It's been a problem working with insurance companies. Regardless of hindsight though, this new management team with Mike at the helm less than a year and Dr. Kendall now on board seems to be much stronger and wanting to achieve a higher level of communications with the diabetes world. We know Afrezza is an amazingly simple solution for global diabetics. I'm hopeful this new team will figure out how best to finally communicate this to the world. The upcoming ADA meeting and STAT results might be a planned springboard. Mike stated months ago partners and a larger sales force were desired. Hopefully they're working towards partnerships that could fund a major national marketing campaign and get us over the goal line. BTW, communications with investors was intentionally left out as the bigger issue has been communications within the diabetes community.
|
|
|
|
Post by peppy on Mar 10, 2018 17:04:33 GMT -5
IMO "communication" has been a real problem with Mannkind over the years. It raised its head first when they weren't prepared for Martin Shkreli's surprise communication with the FDA. It was a problem highlighted when the Sanofi deal soured. It's been a problem with titration. It's been a problem with marketing. It's been a problem working with insurance companies. Regardless of hindsight though, this new management team with Mike at the helm less than a year and Dr. Kendall now on board seems to be much stronger and wanting to achieve a higher level of communications with the diabetes world. We know Afrezza is an amazingly simple solution for global diabetics. I'm hopeful this new team will figure out how best to finally communicate this to the world. The upcoming ADA meeting and STAT results might be a planned springboard. Mike stated months ago partners and a larger sales force were desired. Hopefully they're working towards partnerships that could fund a major national marketing campaign and get us over the goal line. BTW, communications with investors was intentionally left out as the bigger issue has been communications within the diabetes community. quote: The upcoming ADA meeting and STAT results might be a planned springboard. reply: Hopefully Mike C and DR. Kendall can figure out a way to make the continuous glucose monitor pictures available. I picture saids a thousand words. The instructions for the STAT study were good. It covered anything our Afrezza users were going to eat. we are good. TI arm will be instructed to dose before the meals and take necessary corrections at 1- and 2-hours after meals to optimize PPBG (Table 1B). Patients who are randomized into the NL arm will continue using their usual prandial insulin dose before meals. |
|
|
|
Post by digger on Mar 10, 2018 18:51:29 GMT -5
Happened to see this article to day about Sanofi and their problem selling their wonder drug cholesterol-lowering drug Praluent. That is the same drug they had the lawsuit with Amgen on and lost. But if you read the article you will see that one of the issues that both Sanofi and Amgen have with the drug is the cost to the payer (insurer) Its way too high and they push back on letting patients receive it. So they have worked on a new Strategy to lower the price to the payer and create a more outcome based prescribing model.
"Now Regeneron and Sanofi are going one step further, agreeing to lower the price for Praluent to match an independent analysis that found it would be cost-effective for the highest-risk patients at a net cost of $4,500 to $8,000 a year. The companies added one condition to the lower price: that health insurers agree to remove the restrictions, like extensive tests and paperwork, that make prescribing the medicine an arduous process for doctors.
“We have to get the whole world to realize this is cost-effective for society and we have to get this drug to the patients who will benefit the most,” said George Yancopoulos, chief scientific officer at Tarrytown, New York-based Regeneron.
www.bloombergquint.com/business/2018/03/10/regeneron-sanofi-cut-heart-drug-s-price-as-trial-disappoints
This is probably the same direction that MannKind HAS to take to become a preferred Insulin product as the Healthcare industry is changing rapidly. I have to just wonder if Mike C knew this in hiring of Dr. David Kendall. MannKind has to work with payers to show Afrezza is the most cost effective Insulin product at either today's cost or a negotiated fixed price cost to the payer in order to gain critical mass. Remove restrictions and make it easier to prescribe Afrezza and we will give you more cost effective pricing. Perhaps a subscription based program.
Payers are adding the term OUTCOME BASED SOLUTIONS to their talking points and it evident as you see some of the recent marriages. CVS Buying Aetna Cigna Buy Express Scripts. Berkshire Hathaway/Amazon / JP Morgan Healthcare joint venture.
Payers want good outcomes for patients at a cheaper prices. I would say that payers want to make money -- as much money as they can. Whatever maximizes their profit margins is what they'll pay for. Given afrezza is only labeled as non-inferior, I think their cooperation would require a pretty extensive trial comparing afrezza to say, humalog, and showing that the total cost -- drug cost plus cost of treating adverse effects, complications, and so on -- of treating with afrezza is lower than the cost of humalog. |
|
